Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,038Revenue $M49.0Net Margin (%)23.3Z-Score7.4
Enterprise Value $M1,018EPS $0.6Operating Margin %30.5F-Score7
P/E(ttm))86.6Cash Flow Per Share $0.6Pre-tax Margin (%)18.8Higher ROA y-yY
Price/Book15.910-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales19.85-y EBITDA Growth Rate %0Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow32.1y-y EBITDA Growth Rate %100.0ROA % (ttm)10.9Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)23.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M20.7ROI % (ttm)10.2Gross Margin Increase y-yN

Gurus Latest Trades with LGND

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LGNDJoel Greenblatt 2014-03-31 Sold Out -0.02%$51.52 - $79.58
($66.37)
$ 50.06-25%Sold Out0
LGNDJoel Greenblatt 2013-12-31 Add0.01%$44.86 - $57.95
($52.33)
$ 50.06-4%Add 124.95%13,803
LGNDJoel Greenblatt 2013-09-30 Buy 0.01%$38.69 - $49.66
($45.21)
$ 50.0611%New holding, 6136 sh.6,136
LGNDDaniel Loeb 2011-12-31 Sold Out -0.46%$10.59 - $15.73
($12.77)
$ 50.06292%Sold Out0
LGNDGeorge Soros 2011-09-30 Sold Out -0.0017%$10.89 - $15.95
($13.18)
$ 50.06280%Sold Out0
LGNDDaniel Loeb 2011-06-30 Add0.16%$9.56 - $12.02
($10.55)
$ 50.06374%Add 110.73%705,016
LGNDGeorge Soros 2011-06-30 Buy $9.56 - $12.02
($10.55)
$ 50.06374%New holding, 10000 sh.10,000
LGNDGeorge Soros 2009-12-31 Sold Out $9.96 - $14.16
($12.06)
$ 50.06315%Sold Out0
LGNDGeorge Soros 2009-09-30 Buy $13.74 - $18.9
($16.26)
$ 50.06208%New holding, 26900 sh.26,900
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LGND is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LGND Joel Greenblatt 2014-03-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


LGND: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FOEHR MATTHEW WEVP and COO 2014-06-30Buy428$43.7914.32view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-06-30Buy329$43.7914.32view
Herman Melanie JDirector of Accounting 2014-06-30Buy98$43.7914.32view
Herman Melanie JDirector of Accounting 2014-06-09Sell1,100$69.68-28.16view
Berkman Charles SVP, Gen. Counsel & Secretary 2014-05-27Sell7,166$66.9-25.17view
BVF PARTNERS L P/IL 2014-03-25Sell78,226$70.09-28.58view
Davis Todd CDirector 2014-03-19Sell7,500$79.57-37.09view
LAMATTINA JOHN LDirector 2014-03-18Sell5,000$78.83-36.5view
Sabba Stephen LDirector 2014-02-27Sell500$72.25-30.71view
KNOTT DAVID MDirector 2014-02-20Sell900$72.97-31.4view

Press Releases about LGND :

Quarterly/Annual Reports about LGND:

News about LGND:

Articles On GuruFocus.com
Ligand Pharmaceuticals - Severe competitive threat to key royalty program and “going concern” ri Jun 19 2014 
5 Hot Stocks to Consider Now Mar 30 2012 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) May 05 2010 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 09 2009 
Ligand to Acquire Neurogen for Stock and Contingent Value Rights Aug 24 2009 
Ligand Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 04 2009 
Ligand Pharmaceuticals Announces Second Quarter Results Aug 03 2009 
Ligand Announces Fourth Quarter and Full Year 2008 Consolidated Financial Results Feb 12 2009 
Ligand to Hold Fourth Quarter Results Conference Call on February 12 Jan 29 2009 

More From Other Websites
Ligand Partner GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million Jul 23 2014
Ligand Partner GSK Announces Record Quarterly Promacta™/Revolade™ Revenue of $92 Million Jul 23 2014
Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to... Jul 22 2014
Ligand Partner SAGE Therapeutics Receives Fast Track Designation for Captisol-enabled SAGE-547 to... Jul 22 2014
Lemelson Capital Management Announces TTM and Second Quarter 2014 Performance Results for The Amvona... Jul 17 2014
Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program Jul 17 2014
LIGAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 17 2014
Ligand board authorizes $10M repurchase program Jul 17 2014
Ligand Reports Second Quarter Revenues and Announces Share Repurchase Program Jul 17 2014
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% Jul 17 2014
Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum Jul 14 2014
Ligand Chairman Dr. John W. Kozarich Named Director of the Year Honoree by Corporate Directors Forum Jul 14 2014
Ligand Pharmaceuticals - The Bull Case Jul 07 2014
Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ:... Jul 07 2014
Ligand Pharmaceuticals: Appendix Jul 03 2014
Insider Trading Alert - GPS, HCN And LGND Traded By Insiders Jul 02 2014
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors Jun 25 2014
Jeff Cooper: Will S&P Drop to 1,900 After Yesterday's Reversal? Jun 25 2014

Add Notes, Comments or Ask Questions

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide